with a decision by April 2025. Pre-filled syringes of high-dose aflibercept are expected to launch by mid-2025, pending FDA approval. Successful QUASAR trial results support a supplemental biologics ...

paternity and child care leave applications. Despite submitting their representations more than three months ago, they... The Tribune, now published from Chandigarh, started publication on ...